the CEO of a biotech needs many skills. One key skill is to be able to tell the story, and to tell it often.
Another is to attract quality, well-regarded cornerstone investors.
I wish, for instance, OCC could convince a fund like Merchant to buy into OCC, using some of the funds they recently raised for their biotech-only fund.
Look what happened to DXB's share price this morning!
FDA significance, page-462
-
- There are more pages in this discussion • 41 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OCC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
40.0¢ |
Change
0.010(2.56%) |
Mkt cap ! $83.83M | |||
| Open | High | Low | Value | Volume |
| 39.0¢ | 40.0¢ | 39.0¢ | $199.1K | 504.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3807 | 39.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 40.0¢ | 3666 | 2 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| OCC (ASX) Chart |